📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Vineet Laboratories Q3 Results: PAT at ₹85.07 Lakhs, Turnaround from YoY Loss
Vineet Laboratories reported a net profit of ₹85.07 Lakhs for the quarter ended December 31, 2025, marking a significant turnaround from a net loss of ₹570.70 Lakhs in the same period last year. Although revenue from operations declined by 13.5% YoY to ₹1,564.83 Lakhs, the company achieved profitability through improved cost efficiencies. For the nine-month period, the company turned profitable with a PAT of ₹38.56 Lakhs compared to a loss of ₹966.61 Lakhs in the previous year. The board also ratified payments for new equipment intended for the production facility mentioned in their recent Rights Issue.
Key Highlights
Net Profit of ₹85.07 Lakhs in Q3 FY26 vs a loss of ₹570.70 Lakhs in Q3 FY25
Revenue from operations stood at ₹1,564.83 Lakhs, down from ₹1,809.93 Lakhs YoY
Nine-month (9M) PAT turned positive at ₹38.56 Lakhs against a loss of ₹966.61 Lakhs in 9M FY25
Earnings Per Share (EPS) improved to ₹0.92 from a negative ₹6.19 YoY
Board ratified advances for Quality Control and RO equipment for a new production facility
💼 Action for Investors
The company has successfully transitioned back to profitability despite a declining top line, suggesting improved operational margins. Investors should watch for revenue scaling once the new production facility and equipment are fully operational.
Vineet Laboratories Gets Trading Approval for 99.87 Lakh Rights Issue Shares
Vineet Laboratories Limited has received final trading approvals from both BSE and NSE for 99,87,258 equity shares allotted under its recent Rights Issue. These shares, issued at a price of Rs. 30 each (Rs. 10 face value plus Rs. 20 premium), are set to commence trading on February 05, 2026. This announcement marks the successful completion of the fundraising process, providing liquidity to the newly issued shares. Investors should be aware that the total outstanding equity has increased, which may lead to dilution of earnings per share (EPS).
Key Highlights
Received trading approval for 99,87,258 equity shares from BSE and NSE.
Shares issued at Rs. 30 per share, including a premium of Rs. 20.
Trading of the new shares is effective from Thursday, February 05, 2026.
Distinctive numbers for the new shares range from 9219009 to 19206266.
💼 Action for Investors
Shareholders who were allotted shares in the rights issue can now trade them on the exchanges. Monitor the stock for potential short-term price volatility as the new supply of shares enters the secondary market.
Vineet Laboratories Allots 99.87 Lakh Equity Shares via Rights Issue at Rs 30 Per Share
Vineet Laboratories has successfully completed its rights issue by allotting 99,87,258 equity shares at a price of Rs 30 per share (including a premium of Rs 20). This capital infusion has raised approximately Rs 29.96 crore for the company. Consequently, the total paid-up equity share capital has more than doubled, increasing from Rs 9.22 crore to Rs 19.21 crore. The allotment follows the terms set in the Letter of Offer dated December 17, 2025.
Key Highlights
Allotment of 99,87,258 equity shares of face value Rs 10 each on a rights basis.
Issue price fixed at Rs 30 per share, representing a total fundraise of approx Rs 29.96 crore.
Total number of equity shares increased from 92,19,008 to 1,92,06,266 post-allotment.
Paid-up share capital expanded from Rs 9,21,90,080 to Rs 19,20,62,660.
The allotment was finalized in consultation with Bigshare Services Private Limited and BSE Limited.
💼 Action for Investors
Investors should track the company's upcoming quarterly results to see how the newly raised capital is deployed for growth. While the capital infusion is positive, shareholders should be aware of the significant equity dilution as the share count has more than doubled.
Vineet Laboratories Extends Rights Issue Closing Date to January 30, 2026
Vineet Laboratories Limited has announced an extension of its ongoing Rights Issue timeline following a committee meeting on January 13, 2026. The last date for On-Market Renunciation has been moved to January 27, 2026, while the overall Issue Closing Date is now January 30, 2026. This extension is intended to provide more time for investors to participate in the fundraising process. Following the closure, the basis of allotment and listing of shares are scheduled for February 2 and February 3, 2026, respectively.
Key Highlights
Last date for On-Market Renunciation of Rights Entitlements extended to January 27, 2026
Rights Issue closing date officially extended to January 30, 2026
Basis of Allotment and Allotment of Shares scheduled for February 2, 2026
Listing of new Equity Shares on BSE and NSE expected by February 3, 2026
💼 Action for Investors
Investors holding Rights Entitlements (REs) should ensure they either subscribe to the issue or sell their REs on the market by January 27 to avoid total value loss. Monitor the share price relative to the rights price to determine if subscription is financially viable.
Vineet Laboratories to Raise ₹29.97 Crore via Rights Issue at ₹30 Per Share
Vineet Laboratories Limited has submitted its Letter of Offer for a Rights Issue aiming to raise approximately ₹29.97 crore. The company will issue 99,87,258 equity shares at a price of ₹30 per share, which includes a premium of ₹20. The rights entitlement ratio is fixed at 13 shares for every 12 shares held by eligible shareholders as of the record date, December 23, 2025. The issue is scheduled to open on January 1, 2026, and close on January 21, 2026.
Key Highlights
Rights issue size of up to 99,87,258 shares aggregating to ₹29.97 Crores
Issue price set at ₹30 per share (Face Value ₹10 + Premium ₹20)
Rights entitlement ratio of 13:12 for shareholders as of December 23, 2025
Subscription period opens on January 01, 2026, and closes on January 21, 2026
On-market renunciation period ends on January 16, 2026
💼 Action for Investors
Existing shareholders should monitor the market price relative to the ₹30 offer price and decide whether to subscribe, renounce, or sell their rights entitlements before the January 16 deadline.
Vineet Laboratories Receives BSE and NSE Approval for Rs 30 Crore Rights Issue
Vineet Laboratories Limited has secured in-principle approvals from both the National Stock Exchange (NSE) and BSE Limited to undertake a Rights Issue of fully paid-up equity shares. The company plans to raise up to Rs 30 Crores through this issue, offering shares with a face value of Rs 10 each. A board meeting is scheduled for December 17, 2025, to finalize the issue price, entitlement ratio, and record date. This capital infusion is expected to strengthen the company's balance sheet, though it will result in equity dilution for existing shareholders who do not participate.
Key Highlights
Received in-principle approval from NSE on December 02, 2025, and BSE on December 16, 2025.
The proposed Rights Issue aims to aggregate up to a total of Rs 30 Crores.
Board meeting scheduled for December 17, 2025, to determine the issue price, entitlement ratio, and record date.
The issue involves fully paid-up equity shares with a face value of Rs 10 each.
💼 Action for Investors
Existing shareholders should wait for the announcement of the issue price and entitlement ratio to assess the discount offered compared to the market price. Investors should decide whether to subscribe to avoid dilution or sell their rights entitlements if the company allows renunciation.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to Dec 17 for Price Finalization
Vineet Laboratories Limited has adjourned its Rights Issue Committee meeting from December 16 to December 17, 2025. The committee is scheduled to finalize critical details including the Issue Price, Entitlement Ratio, and Record Date for the proposed capital raise. This delay is intended to facilitate the receipt of in-principle approval from BSE Limited. Investors should monitor the upcoming announcement as it will define the terms of equity dilution and the cost of new shares.
Key Highlights
Rights Issue Committee meeting adjourned from December 16 to December 17, 2025.
Committee to determine key modalities: Issue Price, Entitlement Ratio, and Record Date.
Finalization is subject to receiving in-principle approval from BSE Limited.
The initial meeting on December 16 lasted only 30 minutes (6:20 P.M. to 6:50 P.M.) before adjournment.
💼 Action for Investors
Wait for the finalized terms on December 17 to evaluate the attractiveness of the rights issue price compared to the current market price. Assess the potential dilution effect once the entitlement ratio is announced.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to December 16, 2025
Vineet Laboratories Limited has adjourned its Rights Issue Committee meeting, originally scheduled for December 15, 2025, to December 16, 2025. The committee is expected to finalize critical details including the Issue Price, Entitlement Ratio, and Record Date for the upcoming rights issue. This adjournment is intended to allow time for the receipt of in-principle approval from the BSE. The meeting on December 15 lasted only 20 minutes before the decision to adjourn was made.
Key Highlights
Rights Issue Committee meeting adjourned from December 15 to December 16, 2025
Committee to determine Issue Price, Entitlement Ratio, and Record Date
Adjournment pending in-principle approval from BSE Ltd
The initial meeting on December 15 commenced at 7:00 PM and was adjourned at 7:20 PM
💼 Action for Investors
Investors should wait for the adjourned meeting's outcome on December 16 to understand the pricing and dilution impact of the rights issue. Compare the announced issue price with the current market price to determine the attractiveness of the offer.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to December 12, 2025
Vineet Laboratories Limited has announced the adjournment of its Rights Issue Committee meeting, originally scheduled for December 11, 2025, to December 12, 2025. The committee is expected to finalize critical terms of the proposed fundraising, including the Issue Price, Entitlement Ratio, and Record Date. This delay is reportedly to facilitate the receipt of in-principle approval from BSE Ltd. The initial meeting on December 11 lasted only 20 minutes before the adjournment was called.
Key Highlights
Rights Issue Committee meeting adjourned from December 11 to December 12, 2025
Committee to determine Issue Price, Entitlement Ratio, and Record Date for the proposed Rights Issue
Finalization is subject to receiving in-principle approval from BSE Ltd
The meeting on December 11 commenced at 6:00 PM and was adjourned by 6:20 PM
💼 Action for Investors
Investors should wait for the adjourned meeting's outcome on December 12 to evaluate the rights issue price and potential equity dilution.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to Dec 11, 2025
Vineet Laboratories Limited has adjourned its Rights Issue Committee meeting, which was originally scheduled for December 9, 2025. The meeting is now set to reconvene on Thursday, December 11, 2025, to finalize the terms of the proposed fundraising. The committee is expected to determine the Issue Price, Entitlement Ratio, and Record Date during this session. This adjournment is necessary to await the in-principle approval from the BSE Limited.
Key Highlights
Rights Issue Committee meeting adjourned from December 9 to December 11, 2025
Meeting will finalize critical details including Issue Price and Entitlement Ratio
Adjournment is pending the receipt of in-principle approval from BSE Ltd
The initial meeting on December 9 lasted only 20 minutes before adjournment
💼 Action for Investors
Investors should monitor the upcoming announcement on December 11 for specific rights issue terms. Evaluate the issue price relative to the current market price to determine the attractiveness of the offer.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to December 9, 2025
Vineet Laboratories Limited has announced the adjournment of its Rights Issue Committee meeting, originally scheduled for December 6, 2025. The meeting is now rescheduled for Tuesday, December 9, 2025, as the company awaits in-principle approval from BSE Limited. During the upcoming session, the committee is expected to finalize critical details including the Issue Price, Entitlement Ratio, and Record Date. This fundraise is a significant event for the company's capital structure and liquidity.
Key Highlights
Rights Issue Committee meeting adjourned from December 6 to December 9, 2025
Committee to decide on Issue Price, Entitlement Ratio, and Record Date
Adjournment necessitated by pending In-principle approval from BSE Ltd
The initial meeting on Dec 6 lasted only 30 minutes before being adjourned
💼 Action for Investors
Investors should monitor the announcement on December 9 for the rights issue price and ratio to assess potential dilution and investment value.
Vineet Laboratories Rights Issue Committee Meeting Adjourned to Dec 6
Vineet Laboratories has adjourned its Rights Issue Committee meeting, which commenced on December 3, 2025, at 3:00 P.M., to December 6, 2025. The adjournment is to allow the committee to further consider the Issue Price, Entitlement Ratio, Record date, Issue opening and closing dates, and other modalities of the proposed Rights Issue. This is pending receipt of in-principle approval from BSE Ltd. The initial meeting on December 3rd lasted from 3:00 P.M. to 4:00 P.M.
Key Highlights
Rights Issue Committee meeting adjourned to December 6, 2025
Initial meeting commenced on December 3, 2025, at 3.00 P.M.
Initial meeting adjourned at 4.00 P.M.
Considering Issue Price, Entitlement Ratio, Record date, Issue opening and closing dates
💼 Action for Investors
Investors should monitor for the announcement of the Issue Price, Entitlement Ratio, Record date, and Issue dates on December 6, 2025. Evaluate the terms of the rights issue to determine whether to participate.